We are rapidly demystifying cancers, exposing the molecular mechanisms underlying tumors and leading the search for the next generation of targeted cancer therapies. We see a future where every cancer and every patient has a cure.



Reprogramming wound cells heals large ulcers and regenerates skin

Professor Juan Carlos Izpisua Belmonte and first author Masakazu Kurita, along with collaborators, have developed a technique to directly convert the cells in an open wound into new skin cells. The approach relies on reprogramming the cells to a stem-cell-like state and may be useful for healing skin damage, countering the effects of aging and helping to better understand skin cancer.

Read News Release
Genes & Development

Salk scientists develop method to manipulate numbers of nuclear pores

VP, Chief Scientific Officer Martin Hetzer and first author Asako McCloskey have devised a method to manipulate numerous individual nuclear pores, which are essential elements of cells that provide controlled ways to move material into and out of a nucleus. The breakthrough may lead to insights into how to stop cancerous cells from proliferating out of control.

Read News Release

Molecular structures of genetic-engineering tool, therapeutic virus revealed

Assistant Professor Dmitry Lyumkis, first author Sriram Aiyer and collaborators used cryo-electron microscopy (cryo-EM)—a cutting-edge technology that enables researchers to capture the structure of complex molecules in unprecedented detail—to show the structure of AAV2, a version of a virus, advancing the technique’s capabilities and the virus’ potential as a delivery vehicle for gene therapies.

In addition, Lyumkis, together with co-corresponding author and Helmsley-Salk Fellow Patrick Hsu, first author Cheng Zhang and colleagues, used cryo-EM to report the detailed molecular structure of CRISPR-Cas13d, a promising enzyme for emerging RNA-editing technology.

Read September 7 News Release
Read September 20 News Release

Sign up for our monthly newsletter.

Latest discoveries, events & more.